A case report describes an award-winning musician with extensive early-life hallucinogen use and examines how that history influenced his overall wellbeing and subsequent opioid experience. The text notes that little is known about the link between psychedelic use and substance abuse in the general population.
Patients with mental illnesses should have the same access to promising experimental therapies, including psychedelics, as patients with other conditions. The principle of early access to experimental treatments, advanced by activist Larry Kramer during the AIDS pandemic, is now standard in medicine for diseases like cancer and infectious diseases. Psychiatry has failed to provide similar expanded access during public health emergencies, psychological crises, and pandemics, despite patient preferences and community needs. The field must align with the rest of medicine and let patient preferences guide policy and law on unapproved medications such as psychedelics.